Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2091371 | 0.85 | MEN1 (0.71) | KMT2AMEN1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL14274485 | 0.85 | MEN1 (0.71) | KMT2AMEN1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL11350134 | 0.85 | MEN1 (0.71) | KMT2AMEN1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL90967 | 0.83 | ALDH1A1 (0.59) | KMT2AMEN1SMN1; SMN2ALDH1A1HPGD | |
| Fluoride SCHEMBL11786773 | 0.83 | MEN1 (0.69) | KMT2AMEN1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2091369 | 0.83 | MEN1 (0.69) | KMT2AMEN1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL18131322 | 0.83 | TDP1 (0.52) | KMT2AMEN1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL7211300 | 0.83 | NPC1 (0.66) | KMT2AMEN1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL19462539 | 0.82 | TAS1R3 (0.61) | KMT2AMEN1ALDH1A1HTTRAB9A | |
| SCHEMBL23797876 | 0.82 | MEN1 (0.67) | KMT2AMEN1SMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111921465-B | Azo pigment continuous synthesis micro mixer and continuous preparation method thereof | 天津大学 | 2022-02-01 | — | — | CN | claimed |
| CN-110628235-B | Preparation method of pigment yellow 81 | 龙口佳源颜料有限公司 | 2021-07-06 | — | — | CN | claimed |
| CN-109971205-B | Pigment derivative, pigment for polyurethane ink and preparation method of pigment derivative and pigment for polyurethane ink | 龙口联合化学股份有限公司 | 2021-04-02 | — | — | CN | claimed |
| CN-111921465-A | Azo pigment continuous synthesis micro mixer and continuous preparation method thereof | 天津大学 | 2020-11-13 | — | — | CN | claimed |
| CN-110628235-A | Preparation method of pigment yellow 81 | 龙口佳源颜料有限公司 | 2019-12-31 | — | — | CN | claimed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| US-4552981-A | Process for the production of 5-nitro-acet-2,4-xylidine | MOBAY CHEMICAL CORPORATION (US) | 1985-11-12 | — | — | US | claimed |
| US-4341902-A | NITRATION OF ACET-2,4-XYLIDINE | MOBAY CHEMICAL CORPORATION (US) | 1982-07-27 | — | — | US | claimed |
| JP-63125571-A | — | — | None | — | — | JP | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4172146-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-4341902-A | NITRATION OF ACET-2,4-XYLIDINE | MOBAY CHEMICAL CORPORATION (US) | 1982-07-27 | — | — | US | disclosed |
| US-4341902-A | NITRATION OF ACET-2,4-XYLIDINE | MOBAY CHEMICAL CORPORATION (US) | 1982-07-27 | — | — | US | disclosed |
| EP-0049711-A1 | Process for the production of nitro-amino-benzenes | BAYER AG (DE) | 1982-04-21 | — | — | EP | disclosed |
| US-4055439-A | Process for the manufacture of dustless, readily dispersible pigment granules | CIBA-GEIGY CORPORATION (US) | 1977-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | GUSB, SI, ENGASE | KMT2A 4234/4885MEN1 4823/4885SMN1; SMN2 4192/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | KMT2A 4265/4885MEN1 2591/4885SMN1; SMN2 289/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | KMT2A 4298/4885MEN1 2602/4885SMN1; SMN2 272/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | KMT2A 4265/4885MEN1 2591/4885SMN1; SMN2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.